A £90 Million Lawsuit against Reckitt Benckiser

.

A £90 Million Lawsuit against Reckitt Benckiser

While preparing to sue the manufacturers of the heartburn remedy Gaviscon for almost £90 million, NHS has made serious allegations against Reckitt Benckiser saying that the firm had charged doctors with a more expensive version of the medicine when there existed a lesser expensive one.

Recently, in another case, the Office of Fair Trading had fined it £10.2 million after the officials from Reckitt Benckiser admitted breaking UK and EU legislation with the sale of the medicine to the health service.

Reckitt Benckiser's Gaviscon Original was quite a popular medicine and it was very frequently prescribed by the doctors. As its patent had to expire in 2005, other companies got a chance to offer something at a cheaper rate.

But rather than putting forward a generic name allowing cheaper versions to enter into the market, the company left doctors with no option after proposing Gaviscon Advance.

But the whole plan was exposed when an anonymous source revealed, “Reckitt cheated the Health Service. It could have saved the NHS millions of pounds. I felt it had to be exposed”.

Admitting to fail to allow competition, the company said that it had not cheated NHS in any case and it was not happy about the inappropriate language used in the internal correspondence.


Latest News

Feds Expected to Trim Bond Purchases, Could Also Offer Hazy Clues on Interest Ra
After First Six Months of Sales Toyota Remains at Top
McDonald's Franchisee ruling Gives Rise to Business-Labour Arguments
Breakage in Main Pipe Causes Havoc in UCLA
Southwest Airlines to Be Charged a Fine of $12 million Over Issues Related to Re
Zillow to Purchase Trulia; A Merger That Will Create a Real Estate Giant Listing
More than One Third of Americans Debt Offenders
Video Shows Baby Turtles Heading to Sea
Bear Stearns, Alan 'Ace' Greenberg, dies at 86
Former U.S. official Says President Obama Could Restrain Corporate 'Inversions'
As U.S. Stocks Ascend, NYC Pension Funds Report 17.4%  Returns on Investments
Food Scandal in China, Parent Company to Investigate Matters